An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
← catalyst calendarNCT07764146 · readout in 983 d
Sponsored by Voyager Therapeutics (industry) · VYGR — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
18estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-24 | estimated | When the study began enrolling |
| Primary completion | 2029-04-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-04-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer s Disease
Interventions
- Drug: VY1706 Low dose
- Drug: VY1706 Mid dose
- Drug: VY1706 High Dose
- Device: Anti-AAV9 Total Antibody (TAb) Assay
Primary outcome
what the primary-completion date above is the date OFTo characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measures
measured 52 weeks
Permalink · VYGR's whole pipeline · Catalyst calendar · Every registered study · What changed